SynthesisWorld journal of surgical oncology2016
Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Synthesis in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Visualizing research on the prognosis of papillary thyroid cancer: a bibliometric analysis.Frontiers in oncology · 2026Pooled it
- Risk and Prognostic Factors for BRAFBioMed research international · 2022Pooled it
- Pooled it
- Predictive Value of BRAFCurrent medical science · 2018Pooled it
- Early Birds and Thyroid Cancer: Unveiling the Link Between Morningness and Thyroid Cancer Risk Through Mendelian Randomization.Brain and behavior · 2026Article
- Alterations in gut microbiota and metabolic profiling are associated with papillary thyroid cancer and BRAFEndocrine · 2026Article
- Clinical Significance for Risk Stratification of Papillary Thyroid Cancer by TUMORFISHER Circulating Tumor Cell Technique.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The FOXE1 rs965513 polymorphism: a pleiotropic risk locus associated with thyroid function, BRAFScientific reports · 2026Article
- Review
- When cytology misses and ultrasound warns: the predictive role of BRAFV600E mutation in thyroid nodules.Frontiers in endocrinology · 2026Observational
- Papillary thyroid carcinoma: morphological features and association with normalized BRAFV600E allelic frequency; clonality and morphology investigating mutations through microscopy.Thyroid research · 2025Article
- BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.European thyroid journal · 2025Review
- The combined detection of aspiration biopsy, computed tomography and BRAFV600E gene has high diagnostic value for papillary thyroid carcinoma.Archives of endocrinology and metabolism · 2025Article
- HighCancers · 2025Article
- Association BetweenCancers · 2025Article
- BRAF V600E and TERT promoter mutations and their impact on recurrent papillary thyroid carcinoma progression.Endocrine connections · 2025Article
- Comparing Diagnostic Accuracy of BRAF Marker with Surgery Findings in Detecting the Type of Lesion in Patients with Thyroid Nodules with Suspected Fine Needle Aspiration (AUS).Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Contribution of I-131 SPECT/CT uptake on the dynamic risk assessment of papillary thyroid cancer.Quantitative imaging in medicine and surgery · 2025Article
- Clinical outcomes of dabrafenib plus trametinib in locally advanced or metastatic BRAF V600E-mutant papillary thyroid cancer.American journal of cancer research · 2025Article
- Late Pancreatic Metastasis From Papillary Thyroid Carcinoma Diagnosed by Endoscopic Ultrasound-Guided Tissue Acquisition.Ochsner journal · 2025Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study is to perform a meta-analysis to evaluate the associations between the BRAF(V600E) mutation status and aggressive clinicopathological features and poor prognostic factors in papillary thyroid cancer.
methodsA literature search was performed within the PubMed, MEDLINE, Web of Science databases, and EMBASE databases using the Medical Subject Headings and keywords from January 2003 to July 2015. Individual study-specific odds ratios and confidence intervals were calculated, as were the Mantel-Haenszel pooled odds ratios for the combined studies.
resultsSixty-three studies of 20,764 patients were included in the final analysis. Compared with wild-type BRAF, the BRAF(V600E) mutation was associated with aggressive clinicopathological factors, including extrathyroidal extension, higher TNM stage, lymph node metastasis, and recurrence, and was associated with reduced overall survival; however, there was no significant association between the presence of BRAF mutation and distant metastasis.
conclusionsBRAF mutations are closely associated with aggressive clinicopathological characteristics and poorer prognosis in papillary thyroid cancer. Accordingly, aggressive treatment should be considered for papillary thyroid cancer patients with BRAF mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.